Venus Remedies Ltd

Venus Remedies Ltd

₹ 327 -2.43%
19 Apr 3:25 p.m.
About

Incorporated in 1989, Venus Remedies
Ltd is a research based pharmaceutical company and an injectable manufacturer[1]

Key Points

Business Overview:[1][2]
VSR is one of the largest manufacturers of meropenem antibiotics in India. It offers a wide range of pharmaceutical products that cater to various therapeutic areas, including anti infective (antibiotics), antimicrobial resistance, oncology, neurology, pain management, skin
& wound care. Company has 800+ marketing authorizations globally, 100+ patents and 90+ product basket which includes formulations such as injectables,
tablets, and topical preparations

  • Market Cap 437 Cr.
  • Current Price 327
  • High / Low 430 / 186
  • Stock P/E 15.1
  • Book Value 352
  • Dividend Yield 0.00 %
  • ROCE 7.75 %
  • ROE 5.90 %
  • Face Value 10.0

Pros

  • Company is almost debt free.
  • Stock is trading at 0.96 times its book value
  • Company has delivered good profit growth of 23.4% CAGR over last 5 years

Cons

  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company has a low return on equity of 8.67% over last 3 years.
  • Debtor days have increased from 31.9 to 50.7 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
121.94 111.37 129.81 202.56 124.34 142.45 143.08 139.89 116.90 155.64 95.15 167.72 143.42
103.86 106.88 112.99 175.25 111.91 136.91 128.57 126.92 108.80 131.03 84.75 149.93 131.38
Operating Profit 18.08 4.49 16.82 27.31 12.43 5.54 14.51 12.97 8.10 24.61 10.40 17.79 12.04
OPM % 14.83% 4.03% 12.96% 13.48% 10.00% 3.89% 10.14% 9.27% 6.93% 15.81% 10.93% 10.61% 8.39%
6.29 24.05 1.96 2.89 1.22 2.25 1.44 1.79 3.81 3.41 2.26 3.05 2.35
Interest 1.81 0.96 0.14 0.03 0.31 0.00 0.26 0.00 0.15 0.00 0.06 0.06 0.07
Depreciation 8.70 9.38 8.62 8.71 8.64 7.56 7.80 8.99 7.22 8.29 7.55 6.44 6.54
Profit before tax 13.86 18.20 10.02 21.46 4.70 0.23 7.89 5.77 4.54 19.73 5.05 14.34 7.78
Tax % 15.95% -92.91% -16.77% -7.88% -20.21% 0.00% 12.67% 7.63% 27.53% 43.94% 76.63% 30.68% 11.95%
11.66 35.11 11.70 23.15 5.65 0.23 6.89 5.33 3.29 11.06 1.18 9.94 6.85
EPS in Rs 9.45 28.45 8.75 17.32 4.23 0.17 5.15 3.99 2.46 8.27 0.88 7.44 5.12
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
401 459 531 455 407 400 372 322 335 544 597 552 562
298 339 393 366 326 349 333 289 295 490 535 492 497
Operating Profit 103 120 138 89 81 51 39 33 41 54 62 60 65
OPM % 26% 26% 26% 20% 20% 13% 11% 10% 12% 10% 10% 11% 12%
0 0 0 1 2 2 2 -3 -4 43 8 10 11
Interest 27 25 29 41 38 34 35 25 13 13 0 0 0
Depreciation 25 33 40 46 42 40 34 34 32 35 34 32 29
Profit before tax 51 63 69 3 4 -22 -28 -30 -8 49 36 38 47
Tax % 7% 9% 7% -95% 52% 21% -11% 4% -24% -27% -12% 30%
47 57 64 5 2 -17 -31 -29 -10 62 41 27 29
EPS in Rs 48.33 54.36 56.20 4.51 1.49 -13.84 -24.87 -23.15 -8.10 50.05 30.46 19.88 21.71
Dividend Payout % 6% 6% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: 2%
5 Years: 8%
3 Years: 18%
TTM: 4%
Compounded Profit Growth
10 Years: -7%
5 Years: 23%
3 Years: 119%
TTM: 84%
Stock Price CAGR
10 Years: 1%
5 Years: 58%
3 Years: 1%
1 Year: 63%
Return on Equity
10 Years: 3%
5 Years: 4%
3 Years: 9%
Last Year: 6%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Sep 2023
Equity Capital 10 11 11 11 11 12 12 12 12 12 13 13 13
Reserves 289 364 450 445 426 376 350 320 311 374 427 447 458
220 271 289 321 335 312 307 298 220 51 43 42 42
55 72 84 64 70 65 82 102 100 118 97 98 128
Total Liabilities 574 718 834 841 843 765 751 733 644 556 580 601 640
355 401 439 444 452 406 389 364 289 262 241 216 204
CWIP 23 48 68 78 80 66 65 65 25 25 25 26 26
Investments 0 0 0 0 0 0 0 0 0 0 0 20 3
196 268 327 319 310 293 297 304 330 269 314 339 407
Total Assets 574 718 834 841 843 765 751 733 644 556 580 601 640

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
42 52 53 68 47 59 31 45 78 132 41 37
-95 -104 -95 -67 3 -18 8 -11 -5 57 -17 -58
53 55 40 -1 -46 -44 -39 -35 -73 -162 -9 -1
Net Cash Flow -0 3 -2 -1 3 -4 0 -1 -0 27 14 -22

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 36 37 45 51 55 43 46 43 33 21 24 51
Inventory Days 156 178 173 194 219 226 246 286 296 129 118 132
Days Payable 20 26 38 40 38 48 52 72 77 76 47 56
Cash Conversion Cycle 173 190 180 204 236 221 240 257 252 74 95 127
Working Capital Days 88 98 115 146 179 163 144 127 166 74 85 112
ROCE % 17% 15% 14% 6% 5% 2% 1% 1% 2% 8% 8% 8%

Shareholding Pattern

Numbers in percentages

2 Recently
Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
40.81% 40.81% 40.81% 40.81% 41.76% 41.76% 41.76% 41.76% 41.76% 41.76% 41.76% 41.76%
0.02% 0.10% 0.28% 0.33% 0.96% 1.13% 1.07% 1.00% 0.98% 1.03% 1.59% 1.48%
59.17% 59.09% 58.91% 58.86% 57.28% 57.11% 57.19% 57.26% 57.26% 57.21% 56.65% 56.76%
No. of Shareholders 14,41916,61718,23119,95221,18922,01522,24321,71920,49819,26719,56019,913

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents